The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial

Stick, S. M., Foti, A., Ware, R. S., Tiddens, H. A. W. M., Clements, B. S., Armstrong, D. S., Selvadurai, H., Tai, A., Cooper, P. J., Byrnes, C. A., Belessis, Y., Wainwright, C., Jaffe, A., Robinson, P., Saiman, L., & Sly, P. D. (2022). The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. The Lancet Respiratory Medicine, 10(8), 776–784. https://doi.org/10.1016/s2213-2600(22)00165-5
Authors:
Stephen M Stick
Alexia Foti
Robert S Ware
Harm A W M Tiddens
Barry S Clements
David S Armstrong
Hiran Selvadurai
Andrew Tai
Peter J Cooper
Catherine A Byrnes
Yvonne Belessis
Claire Wainwright
Adam Jaffe
Philip Robinson
Lisa Saiman
Peter D Sly
Affiliated Authors:
Lisa Saiman
Subjects:
Publication Type:
Article
Unique ID:
10.1016/S2213-2600(22)00165-5
PMID:
Publication Date:
Data Source:
Scopus

Record Created: